Please assess the completion status of the following clinical trial:

Trial Title: Everolimus Modulation of Anti-tumor T CD4 Immune Responses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status ECOG-WHO 0, 1 or 2~* Metastatic renal cancer~* Patient candidate to everolimus treatment~* signed written informed consent~* fertile women with adequate contraception during the study and until 8 weeks after stopping treatment~Exclusion Criteria:~* Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)~* History of immune deficiency~* Hypersensitivity against rapamycin and derived~* Prior history of other malignancy except for: basal cell carcinoma of the skin, cervical intra-epithelial neoplasia and other cancer curatively treated with no evidence of disease for at least 5 years~* Active autoimmune diseases, HIV, hepatitis C or B virus~* Patients with any medical or psychiatric condition or disease,~* Patients under guardianship, curatorship or under the protection of justice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biological samples (Type: EXPERIMENTAL): Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected.

Based on this trial design, predict the completion outcome and termination type (if applicable).